Transaction #10313 · Form 4 · 0001270905-25-000003
Marker Therapeutics, Inc. · Stock award · Stock Option (Right to Buy)
Marker Therapeutics, Inc. · Transacted November 17, 2025 · Filed November 19, 2025
What does this filing report?
An SEC Form 4 filing for Marker Therapeutics, Inc. records a stock award involving Stock Option (Right to Buy) on November 17, 2025. The reported quantity was 84,411. The filing date is November 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Marker Therapeutics, Inc.
- Company CIK
- 0001094038
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 84,411
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 84,411
- Ownership description
- Not reported
- SEC acceptance time
- Nov 19, 2025, 4:10 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Eansor Norman David ↗
Director
CIK 0001270905
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 84,411
- Conversion / exercise price
- 0.9548
- Exercise date
- Not reported
- Expiration date
- November 17, 2035
Filing footnotes & remarks
- F1
- Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
- F2
- Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.